Amar Kishan, M.D., Chief of GU Radiotherapy at @UCLAJCCC, will host a LIVE Twitter Q&A to discuss interim findings from UCLA's Phase III randomized MIRAGE trial comparing MRI-guided vs. CT-guided SBRTfor localized prostate cancer. Post your questions @AmarUKishan using #MIRAGEQA
